REGULATORY
MHLW to Launch Priority Review Pathway for Overseas Alternatives amid Drug Shortages
Japan’s Ministry of Health, Labor and Welfare (MHLW) will introduce a system allowing priority reviews for overseas alternative medicines when domestic drug shortages severely affect medical care, according to a notification issued on February 27. The new framework will take…
To read the full story
Related Article
- MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
REGULATORY
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





